Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5206210
Max Phase: Preclinical
Molecular Formula: C64H96N22O21S4
Molecular Weight: 1637.87
Associated Items:
ID: ALA5206210
Max Phase: Preclinical
Molecular Formula: C64H96N22O21S4
Molecular Weight: 1637.87
Associated Items:
Canonical SMILES: CC[C@H](C)[C@@H]1NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H]2CCCN2C(=O)[C@H](Cc2cnc[nH]2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H]2CSSC[C@H](NC(=O)CN)C(=O)N[C@@H](CSSC[C@@H](C(N)=O)NC1=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N2
Standard InChI: InChI=1S/C64H96N22O21S4/c1-6-29(4)49-62(105)80-39(50(67)93)22-108-110-25-42-58(101)78-37(20-87)54(97)77-36(14-32-19-69-27-71-32)64(107)85-11-7-9-43(85)59(102)72-30(5)51(94)81-41(24-111-109-23-40(56(99)82-42)73-46(90)17-65)57(100)79-38(21-88)55(98)83-48(28(2)3)61(104)75-33(15-45(66)89)52(95)76-35(13-31-18-68-26-70-31)63(106)86-12-8-10-44(86)60(103)74-34(16-47(91)92)53(96)84-49/h18-19,26-30,33-44,48-49,87-88H,6-17,20-25,65H2,1-5H3,(H2,66,89)(H2,67,93)(H,68,70)(H,69,71)(H,72,102)(H,73,90)(H,74,103)(H,75,104)(H,76,95)(H,77,97)(H,78,101)(H,79,100)(H,80,105)(H,81,94)(H,82,99)(H,83,98)(H,84,96)(H,91,92)/t29-,30-,33-,34-,35-,36-,37-,38-,39-,40-,41-,42-,43-,44-,48-,49-/m0/s1
Standard InChI Key: PGCYEFWMZALOQR-VNWOTCOLSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1637.87 | Molecular Weight (Monoisotopic): 1636.6003 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Liang J, Tae HS, Zhao Z, Li X, Zhang J, Chen S, Jiang T, Adams DJ, Yu R.. (2022) Mechanism of Action and Structure-Activity Relationship of α-Conotoxin Mr1.1 at the Human α9α10 Nicotinic Acetylcholine Receptor., 65 (24.0): [PMID:36137181] [10.1021/acs.jmedchem.2c00494] |
Source(1):